CAREONE Allergy Relief 180 mg Tablets Recalled for Failed Impurities Specifications
Perrigo Company PLC is recalling CAREONE Allergy Relief (Fexofenadine HCL) 180 mg tablets nationwide because stability testing found impurity A out of specification.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall with no reported illness or injury. The hazard is chemical degradation/impurity formation detected during stability testing, a quality control issue with theoretical rather than documented harm, placing this in the Moderate category per the rubric.
Plain-English summary
Perrigo Company PLC is recalling CAREONE Allergy Relief, Fexofenadine Hydrochloride Tablets 180 mg, an over-the-counter antihistamine. The recall affects 28,776 containers distributed nationwide in the USA.
The FDA Class II recall was issued because stability testing results showed impurity A levels that exceeded specification limits. This indicates degradation of the active ingredient or formation of unwanted compounds during the product's shelf life.
Affected products are sold in 30-count bottles (NDC 41520-229-39) and 45-count bottles (NDC 41520-229-95). Specific affected lot numbers and expiration dates are: Lot 0FR0459 (Exp 2/28/2022), Lot 0LR0362 (Exp 6/30/2022), Lot 1BR0462 (Exp 10/31/2022), and Lot 0LR0363 (Exp 6/30/2022). The product was made in the Czech Republic and distributed by Foodhold U.S.A. LLC of Landover, MD.
Consumers who have purchased affected CAREONE Allergy Relief should stop use and dispose of the product or return it to the place of purchase.
The recalled product
- Product
- CAREONE ALLERGY RELIEF (FEXOFENADINE HCL)
- Brand
- CAREONE ALLERGY RELIEF
- Manufacturer
- Perrigo Company PLC
- Category
- Drug — OTC Antihistamine
- Affected units
- 28,776
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot a) 0FR0459
- Exp 2/28/2022
- 0LR0362
- Exp 6/30/2022
- 1BR0462
- Exp 10/31/2022 b) 0LR0363
UPCs (2)
- 341520319846
- 341520319839
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 30 recalled by Perrigo Company PLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 30 products in this recall →Related recalls
Same brand · CAREONE ALLERGY RELIEF
- HighCareone Allergy Relief tablets recalled for failed impurity and degradation specifications
FDA (Drugs) · 2023-07-19
Same manufacturer · Perrigo Company PLC
See all →- ModerateCareOne Severe Congestion Nasal Spray Recalled Due to Contaminated Excipient
FDA (Drugs) · 2022-03-02
- ModerateEquate Children's Pain and Fever Acetaminophen Suspension Recall
FDA (Drugs) · 2022-03-02
- ModerateEqualine Nasal Oxymetazoline HCl Nasal Spray Recalled for Contaminated Excipient
FDA (Drugs) · 2022-03-02
- ModerateUP AND UP Childrens Acetaminophen Recall Due to Contaminated Excipient
FDA (Drugs) · 2022-03-02
- ModerateCVS Infant's Grape Acetaminophen Suspension Recalled for Contaminated Excipient
FDA (Drugs) · 2022-03-02
Same hazard · degradation
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateAniara 5-PLASMA Bivalirudin Calibrator Recalled for Stability Issues
FDA (Devices) · 2026-08-12
- Moderate5-PLASMA Bivalirudin Control Model 5D-44905 Recalled Due to Stability Issues
FDA (Devices) · 2026-08-12
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15